The preparation of the sucrose density gradient should result in a clear separation of the three molar solutions of sucrose (0.8, 1.0, and 1.2 M sucrose). See Figure 3A for an example of the gradient before the protein sample is added. If the gradient is prepared too much in advance, or if it is prepared on a bench surface with vibration from other equipment, the gradient will be compromised and proper separation will not be achieved. If a clear separation of the three solutions is not visible, it is advisable to make a new gradient before adding the protein sample. See Figure 3B for an example of the sucrose gradient when the protein sample is added (black arrow).
Following the centrifugation, there should be clear bands of protein fractions at each interphase (0.32/0.8, 0.8/1.0, 1.0/1.2). In addition a pellet should be visible at the bottom of the tube. See Figure 3C for an example of the fraction bands after ultracentrifugation. If fractions are only diffusely present at the interphase, it is likely that the gradient was compromised and further processing is not advised.
Western blotting of total, SPM and PSD1T protein samples from mouse striatum is demonstrated in Figure 2. The enrichment of synaptic proteins like GluR1, PSD95, and CaMKII, can be visualized by loading a constant amount of protein (10 μg) from total, SPM, and PSD fractions. Perisynaptic proteins like the dopamine transporter (DAT) are enriched in the SPM fraction, but are eliminated in subsequent detergent steps of the PSD enrichment process.
To ensure equivalent loading, protein levels can be visualized on the western blot membrane by staining with Ponceau Red26. Antibody-based “loading controls” are often reported in the literature, but this may be a misnomer since synaptic proteins may be differentially regulated in experimental treatment groups. If an antibody-based “loading control” is desired, it is advisable to first determine equivalent protein loading by Ponceau staining, and then test several reference proteins to identify those that do not change in the different experimental groups.

Figure 1. Workflow of subcellular fractionation to enrich SPM and PSD protein fractions.

Figure 2. Representative western blot of total, SPM, and PSD1T protein from mouse striatum. 10 μg of protein extract were resolved on SDS-denaturing, 10% acrylamide gels, and transferred to PVDF membranes. Subsequently these blots were incubated with primary antibodies for αCaMKII, GluR1, PSD-93, and PSD-95, which are all components of the post-synaptic density. Accordingly, these proteins are enriched in the SPM and PSD fractions. Alternately, blots were incubated with a primary antibody for DAT, which is located in presynaptic membranes in the striatum. While DAT is enriched in the SPM fraction, it is not part of the PSD complex, and immunoreactivity is not observed in the PSD fraction. Antibodies against actin or sodium/potassium ATPase (Na/K pump) can be used as loading controls, although some experimental conditions may affect the levels of these proteins as well and so the appropriate loading control must be determined empirically.

Figure 3. Representative examples of sucrose gradient before and after ultracentrifugation. A. After the gradient is prepared, there should be three phases that are visible when the tube is held up to the light. The white arrows indicate the interphase between 0.8/1.0 M sucrose solutions and 1.0/1.2 M sucrose solutions. B. When the sample is loaded on top of the gradient, it is in a 0.32 M sucrose solution and will rest on top of the 0.8 M sucrose layer. C. After centrifugation, the homogenate will separate into several fractions. The fraction floating at the interphase of 0.8/1.0 M sucrose solutions will be enriched in myelin membranes. The fraction at the interphase of 1.0/1.2 M sucrose solutions represents the SPM fraction that is collected with a needle and syringe. The pellet at the bottom of the tube is enriched for mitochondrial proteins.
| Solutions | HEPES-buffered sucrose | Protease inhibitors | *Phophatase inhibitors |
| 1 M HEPES pH 7.4 | 0.32 M sucrose in 4 mM HEPES (pH 7.4) | 0.25 mM PMSF (stock 250 mM in ethanol, 1,000x) | 10 mM Sodium Fluoride (stock 500 mM, 50x) |
| 4 mM HEPES pH 7.4 | 0.8 M sucrose in 4 mM HEPES (pH 7.4) | 1.5 μg/ml Aprotinin (stock 1.5 mg/ml, 1,000x) | 2.5 mM Sodium Pyrophosphate (stock 250 mM, 100x) |
| ddH2O | 1.0 M sucrose in 4 mM HEPES (pH 7.4) | 10 μg/ml Leupeptin (stock 10 mg/ml, 1,000x) | 1.0 mM b-glycerophosphate (stock 200 mM, 200x) |
| 50 mM HEPES (pH 7.4) 2 mM EDTA | 1.2 M sucrose in 4 mM HEPES (pH 7.4) | 0.1 mg/ml Benzamidine (stock 100 mg/ml, 1,000x) | 5.0 mM Sodium Orthovanadate (stock 500 mM, 100x) |
| | 10 μg/ml Pepstatin (stock 5 mg/ml in ethanol, 500x) | |
Table 1. Required Reagents
| Fraction | Protein fraction | Protein marker |
| P1 | nuclear | histone H127 |
| S1 | cytosol/membranes | calnexin28 (endoplasmic reticulum), a-tubulin29 (cytoskeleton), GAPDH30 (cytosol), 58K golgi protein31 (Golgi apparatus) |
| P2 and P2' | crude synaptosomes | AMPA and NMDA receptor subunits32 |
| S2 and S2' | cytosol/light membranes | nNOS129 (cytosol), GAPDH (cytosol), LAMP133 (lysosome), PEX1434 (peroxisome) |
| P3 | synaptosome/mitochondria | VDAC35 (mitochondria), AMPA and NMDA receptor subunits (synaptosome) |
| S3 | synaptic vesicle | SV28, synaptophysin8 |
| 0.8 M/1.0 M | myelin | myelin basic protein36 |
| 1.0 M/1.2 M | SPM | AMPA and NMDA receptor subunits, presynaptic marker (SNAP258), neurexin32, neuroligin32 |
| 1.2 M P | mitochondria | VDAC35 |
| PSD (1T) | PSD | PSD9332, PSD9532, AMPA and NMDA receptor subunits, neuroligin, PICK132, CaMKII32 |
| TS | presynaptic membranes | SNAP25, Munc1837, Bassoon38, neurexin |
| PSD-2T | enriched PSD | PSD95, AMPA and NMDA receptor subunits, PICK1, CaMKII |
Table 2. List of protein markers to distinguish subcellular fractions